A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/22/2001	WO2001088128A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	WO2001088126A2 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
11/22/2001	WO2001088116A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods
11/22/2001	WO2001088108A1 Neuronal serine-threonine protein kinase
11/22/2001	WO2001088101A2 CELL LINE FOR THE EXPRESSION OF AN α2δ2 CALCIUM CHANNEL SUBUNIT
11/22/2001	WO2001088098A2 Fertilization of aged oocytes
11/22/2001	WO2001087981A2 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
11/22/2001	WO2001087938A2 Polynucleotide sequence encoding a putative cell adhesion molecule
11/22/2001	WO2001087935A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
11/22/2001	WO2001087934A2 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
11/22/2001	WO2001087923A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	WO2001087913A2 Method for treating retinal degeneration with purinergic receptor agonists
11/22/2001	WO2001087895A1 Synthetic process for the manufacture of an ecteinaschidin compound
11/22/2001	WO2001087894A1 Antitumoral analogs of et-743
11/22/2001	WO2001087893A1 Process for preparing a pure, pharmacopoeial grade amorphous form of cefuroxime axetil
11/22/2001	WO2001087892A1 Crf receptor antagonists
11/22/2001	WO2001087890A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
11/22/2001	WO2001087889A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087887A2 Neuroprotective and anti-proliferative compounds
11/22/2001	WO2001087886A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087884A2 Polyketide derivatives
11/22/2001	WO2001087883A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087882A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
11/22/2001	WO2001087881A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	WO2001087880A1 1-(benzothiazol-2-yl)pyrazole derivatives and cox-2 inhibitors containing the same
11/22/2001	WO2001087879A1 New thiochromane derivatives and their use as thrombin inhibitors
11/22/2001	WO2001087877A1 Novel thiophenamide compounds
11/22/2001	WO2001087874A1 Process for producing crystal
11/22/2001	WO2001087870A1 Hydroxamic acid derivatives
11/22/2001	WO2001087869A1 A pharmaceutical composition containing the extract of saururus chinensis baill useful as and anticancer agent and a process for the preparation thereof
11/22/2001	WO2001087866A1 Cyclohexyl derivatives and their use as therapeutic agents
11/22/2001	WO2001087854A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	WO2001087849A2 Modulators of tnf- alpha signaling
11/22/2001	WO2001087846A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
11/22/2001	WO2001087844A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087841A1 Novel polymorph v of torasemide
11/22/2001	WO2001087840A1 Propanoic acid derivatives as integrin receptor antagonists
11/22/2001	WO2001087839A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	WO2001087838A1 Cyclohexane derivatives and their use as therapeutic agents
11/22/2001	WO2001087836A1 Novel $g(b crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
11/22/2001	WO2001087835A1 Α crystalline form of perindopril tert-butylamine salt
11/22/2001	WO2001087834A1 Melanin-concentrating hormone antagonist
11/22/2001	WO2001087830A2 Substituted thioacetamides
11/22/2001	WO2001087828A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
11/22/2001	WO2001087824A2 7-substituted fused ring tetracycline compounds
11/22/2001	WO2001087823A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives
11/22/2001	WO2001087810A1 Methods for the production of d-chiro-inositol and the use of d-chiro-inositol obtained therefrom
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087375A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087372A1 Drug combinations useful for prevention of restenosis
11/22/2001	WO2001087355A1 Lipophilic medicament
11/22/2001	WO2001087350A2 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	WO2001087348A2 Multifunctional nanodevice platform
11/22/2001	WO2001087346A2 Dendritic cells loaded with toxic substances
11/22/2001	WO2001087345A1 Stable polymeric micelle-type drug composition and method for the preparation thereof
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087341A1 Agents for preventing or ameliorating insulin resistance and/or obesity
11/22/2001	WO2001087335A2 Method for selectively inhibiting ghrelin action
11/22/2001	WO2001087334A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	WO2001087316A2 Composition and method for increasing testosterone levels
11/22/2001	WO2001087315A1 Treatment or prevention of metabolic bone disorder
11/22/2001	WO2001087313A1 Combination chemotherapy
11/22/2001	WO2001087312A1 Polyethylene glycol (peg) polymers for the promotion of angiogenesis
11/22/2001	WO2001087311A1 Immunopotentiator
11/22/2001	WO2001087310A1 Process for reducing antibody response against xenografts
11/22/2001	WO2001087308A1 Treatment of fibromyalgia and chronic fatigue syndrome
11/22/2001	WO2001087307A2 Compositions and methods for the treatment of cancer
11/22/2001	WO2001087306A2 Compositions and methods for the treatment of colorectal cancer
11/22/2001	WO2001087305A2 Method for treating functional dyspepsia using alosetron
11/22/2001	WO2001087304A1 Ophthalmic solution
11/22/2001	WO2001087303A1 Aqueous liquid preparation
11/22/2001	WO2001087301A1 Methods for treatment of inflammatory diseases
11/22/2001	WO2001087300A1 Creatinine biosensor
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087298A1 Water-based liquid preparation
11/22/2001	WO2001087297A1 Cannabinoid drugs
11/22/2001	WO2001087296A1 Methods for decreasing cell proliferation based on (3r, 4r)δ8-tetrahydrocannabinol-11-oic acids
11/22/2001	WO2001087295A1 Methods for decreasing cell proliferation based on (3r, 4r)-δ8-tetrahydrocannabinol-11-oic acids
11/22/2001	WO2001087294A1 Phosphate transport inhibitors
11/22/2001	WO2001087293A1 -secretase inhibitors
11/22/2001	WO2001087291A1 Compositions normalizing circadian rhythm
11/22/2001	WO2001087290A1 Decoquinate, 4-hydroxyquinolones and napthoquinones for the prevention and treatment of equine protozoal myeloencephalitis caused by sarcocystis neurona hughesi and other apicomplexan protozoans
11/22/2001	WO2001087289A2 Propofol for treatment of sepsis
11/22/2001	WO2001087288A2 Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
11/22/2001	WO2001087287A2 Use of pyrazole derivatives for treating infertility
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087283A2 New use of citreamicins
11/22/2001	WO2001087282A2 Pepsin inhibition by alginates
11/22/2001	WO2001087281A2 Method for enhancing cognitive function
11/22/2001	WO2001087280A2 Means for treating attacks of auto-immune diseases
11/22/2001	WO2001087278A1 Insulin formulation for inhalation
11/22/2001	WO2001087276A1 Hydrogel composition for transdermal drug delivery
11/22/2001	WO2001087272A2 Encapsulating a toxic core within a non-toxic region in an oral dosage form
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087266A1 Stabilized aqueous suspensions for parenteral use
11/22/2001	WO2001087264A2 Rapidly disintegrating solid oral dosage form

1 ... 5960 5961 5962 5963 5964 5965 5966 5967 5968 5969 5970 5971 5972 5973 5974 5975 5976 5977 5978 5979 5980 ... 7860